Ten Commandments for 2021 Guidelines on Valvular Heart Disease

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

Since the latest version to the Valvular Heart Disease Guidelines from the European Society of Cardiology, plenty of evidence has been accumulating, finally leading to this updated version. 

In this regard, below you will find what has been called “10 commandments” that sum up this new document, to keep you in the loop. 

  • The incidence of degenerative valvulopathy continues to increase in industrialized countries, with the elderly as the most affected seeing as they present multiple comorbidities. On the other hand, rheumatic heart disease continues to be fairly frequent in developing countries. 
  • We give emphasis to patient centered assessments. When considering an intervention, we should assess patient expectations and values. This can only be carried out by a multidisciplinary team working in a specialized heart valve center. 
  • Echocardiograms are key to the diagnosis of valvulopathy, to measure severity and establish prognosis. Other studies such as CT scans, MRIs and biomarkers are starting to play a more central role. 
  • Based on randomized trial outcomes on its intervention, we have new definitions of severity in secondary mitral valve regurgitation.  
  • To prevent stroke in patients with atrial fibrillation, we recommend direct anticoagulants in patients with aortic stenosis, mitral or aortic regurgitation and patients with bioprosthesis 3 months post implantation. We recommend single antiaggregation for patients undergoing TAVR with no other anticoagulation indication. 
  • In places with high surgical experience and post operative support, you can consider early intervention in asymptomatic patients at low risk of aortic stenosis, aortic or mitral regurgitation, or tricuspid regurgitation. 

Read also: New Valvular Heart Disease Guidelines with Key TAVI and Mitral Regurgitation Updates.


  • New information on randomized controlled trials comparing TAVR against CABG have contributed to clarify the role each procedure has in the treatment of low-risk patients. Choosing the most adequate strategy (TAVR vs CABG) should be in the hands of a multidisciplinary team who will consider patient age, surgical risk, clinical and anatomical characteristics (particularly femoral approach feasibility) center experience and results and, last but not least, patient preference. 
  • Edge to Edge repair has been compared to optimal medical treatment in secondary mitral regurgitation, resulting in an upgraded recommendation of this strategy for patients meeting the criteria that predict clinical improvement. 
  • A lot of information has been published on valve in valve; this has led to upgrading its recommendation. 
  • Lastly, encouraged by the published information, there is a potential role for transcatheter tricuspid repair in inoperable asymptomatic patients with tricuspid failure

Original Title: The “ten commandments” for the 2021 ESC/EACTS Guidelines on valvular heart disease.

Reference: Alec Vahanian et al. Eur Heart J. 2021 Nov 1;42(41):4207-4208. doi: 10.1093/eurheartj/ehab626.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Transradial Aortic Valvuloplasty: Is Minimalism Worth It?

Balloon aortic valvuloplasty (BAV) has historically been used either as a bridge strategy, an assessment tool, or even palliative treatment in severe aortic stenosis...

Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring

Atrial fibrillation (AF) is a recognized complication following percutaneous closure of a patent foramen ovale (PFO), with reported incidences of up to 30% during...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....